- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
Submission of a phase II clinical trial protocol for subcutaneous injection formulation of FB825 in patients with moderate-to-severe atopic dermatitis
Fespixon is included in the 2024 TSOC/TSPS Joint Consensus and has been published by a renowned SCI journal, Acta Cardiologica Sinica.
Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in Thailand.
Oneness Biotech to Present at the 42nd Annual J.P. Morgan Healthcare Conference